Background: Research suggests that yohimbine hydrochloride (YOH), a noradrenaline agonist, can facilitate fear extinction. It is thought that the mechanism of enhanced emotional memory is stimulated through elevated noradrenaline levels. This randomized placebo-controlled trial examined the potential exposure-enhancing effects of YOH in a clinical sample of participants meeting DSM-IV criteria for a specific phobia (fear of flying). Methods: Sixty-seven participants with fear of flying were randomized to 4 sessions of virtual reality exposure therapy (VRET) combined with YOH (10 mg), or 4 sessions of VRET combined with a placebo. Treatment consisted of 4 weekly 1-hour exposure sessions consisting of two 25-minute virtual flights. At pre- and post- treatment, fear of flying was assessed. The YOH or placebo capsules were administered 1 h prior to exposures. The manipulation of the noradrenaline activity was confirmed by salivary α-amylase (sAA) samples taken pre-, during and post-exposure. Results: Forty-eight participants completed treatment. Manipulation of noradrenaline levels with YOH was successful, with significantly higher levels of sAA in the YOH group when entering exposure. Results showed that both groups improved significantly from pre- to post-treatment with respect to anxiety reduction. However, although the manipulation of noradrenaline activity was successful, there was no evidence that YOH enhanced outcome. Conclusions: Participants improved significantly on anxiety measures independently of drug condition, after 4 sessions of VRET. These data do not support the initial findings of exposure-enhancing effects of YOH in this dosage in clinical populations.

Keywords:
Cognitive-behavioral therapy, Exposure, Fear extinction, Norepinephrine, Placebo, Randomized clinical trial, Virtual reality, Yohimbine hydrochloride
1.
Rescorla RA: Experimental extinction; in Mowrer RR, Klein SB (ed): Handbook of Contemporary Learning Theories. Mahwah, Erlbaum, 2001, pp 119–154.
2.
Bouton ME: Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry 2002;52:976–986.
3.
Emmelkamp PMG, Bouman TK, Scholing A: Anxiety Disorders: A Practioner’s Guide. Chichester, John Wiley & Sons, 1992.
4.
Norton PJ, Price EC: A meta-analytic review of adult cognitive behavioral treatment outcome across anxiety disorders. J Nerv Ment Dis 2007;195:521–531.
5.
Powers MB, Sigmarsson SR, Emmelkamp PMG: A meta-analytic review of psychological treatments for social anxiety disorder. Int J Cogn Ther 2008;12:94–113.
6.
Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al: Cognitive enhancers as aduncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004;61:1136–1144.
7.
Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al: Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006;63:298–304.
8.
Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al: A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008;63:544–549.
9.
Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al: D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007;62:835–838.
10.
Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, et al: D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007;22:230–237.
11.
Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al: Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008;165:335–341.
12.
Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al: Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010;67:365–370.
13.
Siegmund A, Golfels F, Finck C, Halisch A, Räth D, Plag J, Ströhle A: D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res DOI: 10.1016/j.jpsychires. 2011.01.020.
14.
Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, et al: Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002;5:301–307.
15.
Cain CK, Blouin AM, Barad M: Adrenergic transmission facilitates extinction of conditional fear in mice. Learn Mem 2004;11:179–187.
16.
Morris RW, Bouton ME: The effect of yohimbine on the extinction of conditioned fear: a role for context. Behav Neurosci 2007;121:501–514.
17.
O’Carroll RE, Drysdale E, Cahill L, Shajahan P, Ebmeier KP: Stimulation of the noradrenergic system enhances and blockade reduces memory for emotional material in man. Psychol Med 1999;29:1083–1088.
18.
Southwick SM, Davis M, Horner B, Cahill L, Morgan CA, Gold PE, Bremner JD, Charney DC: Relationship of enhanced norepinephrine activity during memory consolidation to enhanced long-term memory in humans. Am J Psychiatry 2002;159:1420–1422.
19.
Powers MB, Smits JAJ, Otto MW, Sanders C, Emmelkamp PMG: Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 2009;23:350–356.
20.
Holmes A, Quirk GJ: Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders – the case of yohimbine. Trends Pharmacol Sci 2009;31:2–7.
21.
Charney DS, Woods SW, Goodman WK, Henninger GR: Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987;144:1030–1036.
22.
Peskind ER, Wingersson D, Murray S, Pascually M, Dobie DJ, Le Corre P, Le Verge R, Veith RC, Raskind MA: Effects of Alzheimer’s disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 1995;52:774–782.
23.
Van Stegeren AH, Rohleder N, Everaerd W, Wolf OT: Salivary alpha amylase as marker for adrenergic activity during stress: effect of betablockade. Psychoneuroendocrinology 2006;31:137–141.
24.
Mueller D, Olivera-Figueroa LA, Pine DS, Quirk GJ: The effects of yohimbine and amphetamine on fear expression and extinction in rats. Psychopharmacology 2009;204:599–606.
25.
Otto MW, Basden SL, McHugh K, Kantak KM, Deckersbach T, Cather C, Goff DC, Hofmann SG, Berry AC, Smits JAJ: Effects of D-cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychother Psychosom 2009;78:49–54.
26.
Meyerbröker K, Emmelkamp PMG: Virtual reality exposure therapy in anxiety disorders: a systematic review of process-and-outcome studies. Depress Anxiety 2010;27:933–944.
27.
Rothbaum BO, Hodges L, Anderson P, Price L, Smith S: Twelve-months follow-up of virtual reality and standard exposure therapies for fear of flying. J Consult Clin Psychol 2002;70:428–432.
28.
Mühlberger A, Wiedemann G, Pauli P: Efficacy of a one-session virtual reality exposure treatment for fear of flying. Psychother Res 2003;13:323–336.
29.
Rothbaum BO, Zimand E, Hodges L, Lang D, Wilson J: Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying. Behav Ther 2006;37:80–90.
30.
Mühlberger A, Weik A, Pauli P, Wiedemann G: One-session virtual reality exposure treatment for fear of flying: 1-year follow-up and graduation flight accompaniment effects. Psychother Res 2006;16:26–40.
31.
Krijn M, Emmelkamp PMG, Olafsson RP, Bouwman M, van Gerwen LJ, Spinhoven P, Schuemie MJ, van der Mast CAPG: Fear of flying treatment methods: virtual reality exposure vs. cognitive behavioral therapy. Aviat Space Environ Med 2007;78:121–128.
32.
Parsons TD, Rizzo AA: Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis. J Behav Ther Exp Psychiatry 2008;39:250–261.
33.
Powers MB, Emmelkamp PMG: Virtual reality exposure therapy for anxiety disorders: a meta-analysis. J Anxiety Disord 2008;22:561–569.
34.
Nater UM, Rohleder N: Salivary alpha-amylase as a non-invasive biomarker for the sympathetic nervous system: current state of research. Psychoneuroendocrinology 2009;34:486–496.
35.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Text Revision, ed 4. Washington, APA, 2000.
36.
Wolpe J: The Practice of Behavior Therapy, ed 4. New York, Pergamon Press, 1990.
37.
Venhuis BJ, Barends DM, Zwaagstra ME, de Kaste D: Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra (RIVM report 370030001/2007). Amsterdam, Dutch Health Care Inspectorate (IGZ), 2007.
38.
Vasa RA, Pine DS, Masten CL, Vythilingam M, Collin C, Charney DS, Neumeister A, Mogg K, Bradley BP, Bruck M, Monk CS: Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology 2009;204:445–455.
39.
Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, et al: Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:266–274.
40.
Swann AC, Birnbaum D, Jagar AA, Dougherty DM, Moeller FG: Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol Psychiatry 2005;57:1209–1211.
41.
Hamner MB, Hitri A: Plasma beta-endorphin levels in post-traumatic stress disorder: a preliminary report on response to exercise-induced stress. J Neuropsychiatry Clin Neurosci 1992;4:59–63.
42.
Ernst E, Pittler MH: Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159:433–436.
43.
Vogt HJ, Brandl P, Kockott G, Schmitz JR, Wiegand MH, Schadrack J, et al: Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res 1997;9:155–161.
44.
Van Groenestijn MAC, Akkerhuis GW, Kupka RW, Schneider N, Nolen WA: Structured Clinical Interview for DSM-IV Axis I Disorders, SCID-I (Dutch translation). Lisse, Swets and Zeitlinger, 1996.
45.
Van Gerwen LJ, Spinhoven P, Van Dyck R, Diekstra RFW: Construction and psychometric characteristics of two self-report questionnaires for the assessment of fear of flying. Psychol Assess 1999;11:146–158.
46.
Nousi A, van Gerwen L, Spinhoven P: The Flight Anxiety Situations Questionnaire and the Flight Anxiety Modality Questionnaire: norms for people with fear of flying. Travel Med Infect Dis 2008;6:305–310.
47.
Granger DA, Kivlighan KT, el-Sheikh M, Gordis EB, Stroud LR: Salivary α-amylase in biobehavorial research. Ann NY Acad Sci 2007;1098:122–144.
48.
Field A: Discovering Statistics Using SPSS, ed 3. London, Sage, 1996.
49.
Anker JJ, Carroll ME: Sex differences in the effect of allopregnanolone on yohimbine-induced reinstatement of cocaine seeking in rats. Drug Alcohol Depend 2010;107:264–267.
50.
Kazdin AE: Research Design in Clinical Psychology, ed 4. Boston, Pearson Education, 2003.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.